vs
Side-by-side financial comparison of Affinity Bancshares, Inc. (AFBI) and Tonix Pharmaceuticals Holding Corp. (TNXP). Click either name above to swap in a different company.
Affinity Bancshares, Inc. is the larger business by last-quarter revenue ($8.6M vs $5.4M, roughly 1.6× Tonix Pharmaceuticals Holding Corp.). Affinity Bancshares, Inc. runs the higher net margin — 24.9% vs -870.3%, a 895.2% gap on every dollar of revenue. On growth, Tonix Pharmaceuticals Holding Corp. posted the faster year-over-year revenue change (108.8% vs 12.8%). Affinity Bancshares, Inc. produced more free cash flow last quarter ($11.2M vs $-41.5M). Over the past eight quarters, Tonix Pharmaceuticals Holding Corp.'s revenue compounded faster (47.4% CAGR vs 8.1%).
Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.
AFBI vs TNXP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.6M | $5.4M |
| Net Profit | $2.1M | $-46.9M |
| Gross Margin | — | 80.4% |
| Operating Margin | 35.9% | -895.8% |
| Net Margin | 24.9% | -870.3% |
| Revenue YoY | 12.8% | 108.8% |
| Net Profit YoY | 58.5% | -112.2% |
| EPS (diluted) | $0.34 | $-4.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.6M | $5.4M | ||
| Q3 25 | $8.4M | $3.3M | ||
| Q2 25 | $8.3M | $2.0M | ||
| Q1 25 | $7.8M | $2.4M | ||
| Q4 24 | $7.6M | $2.6M | ||
| Q3 24 | $8.0M | $2.8M | ||
| Q2 24 | $8.3M | $2.2M | ||
| Q1 24 | $7.3M | $2.5M |
| Q4 25 | $2.1M | $-46.9M | ||
| Q3 25 | $2.2M | $-32.0M | ||
| Q2 25 | $2.2M | $-28.3M | ||
| Q1 25 | $1.8M | $-16.8M | ||
| Q4 24 | $1.3M | $-22.1M | ||
| Q3 24 | $1.7M | $-14.2M | ||
| Q2 24 | $1.0M | $-78.8M | ||
| Q1 24 | $1.3M | $-14.9M |
| Q4 25 | — | 80.4% | ||
| Q3 25 | — | 58.4% | ||
| Q2 25 | — | -63.8% | ||
| Q1 25 | — | 61.2% | ||
| Q4 24 | — | 54.2% | ||
| Q3 24 | — | 44.9% | ||
| Q2 24 | — | -52.5% | ||
| Q1 24 | — | 33.1% |
| Q4 25 | 35.9% | -895.8% | ||
| Q3 25 | 34.9% | -1005.1% | ||
| Q2 25 | 34.1% | -1416.2% | ||
| Q1 25 | 30.8% | -660.9% | ||
| Q4 24 | 21.1% | -870.6% | ||
| Q3 24 | 28.5% | -551.2% | ||
| Q2 24 | 16.2% | -3501.6% | ||
| Q1 24 | 24.0% | -860.2% |
| Q4 25 | 24.9% | -870.3% | ||
| Q3 25 | 26.5% | -972.9% | ||
| Q2 25 | 25.9% | -1415.0% | ||
| Q1 25 | 23.4% | -692.8% | ||
| Q4 24 | 17.7% | -856.2% | ||
| Q3 24 | 21.7% | -503.6% | ||
| Q2 24 | 12.5% | -3567.8% | ||
| Q1 24 | 18.2% | -601.9% |
| Q4 25 | $0.34 | $-4.28 | ||
| Q3 25 | $0.34 | $-3.59 | ||
| Q2 25 | $0.33 | $-3.86 | ||
| Q1 25 | $0.28 | $-2.84 | ||
| Q4 24 | $0.21 | $2302.65 | ||
| Q3 24 | $0.26 | $-22.68 | ||
| Q2 24 | $0.16 | $-1920.85 | ||
| Q1 24 | $0.20 | $-535.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $53.9M | $207.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $127.0M | $245.2M |
| Total Assets | $881.7M | $277.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.9M | $207.6M | ||
| Q3 25 | $84.8M | $190.1M | ||
| Q2 25 | $89.7M | $125.3M | ||
| Q1 25 | $74.7M | $131.7M | ||
| Q4 24 | $41.4M | $98.8M | ||
| Q3 24 | $52.3M | $28.2M | ||
| Q2 24 | $50.4M | $4.2M | ||
| Q1 24 | $61.4M | $7.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $8.7M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | — | $10.1M | ||
| Q1 24 | — | $10.8M |
| Q4 25 | $127.0M | $245.2M | ||
| Q3 25 | $125.4M | $231.1M | ||
| Q2 25 | $124.1M | $168.0M | ||
| Q1 25 | $122.3M | $180.4M | ||
| Q4 24 | $129.1M | $139.6M | ||
| Q3 24 | $128.4M | $74.2M | ||
| Q2 24 | $125.1M | $42.1M | ||
| Q1 24 | $123.3M | $108.1M |
| Q4 25 | $881.7M | $277.2M | ||
| Q3 25 | $925.2M | $252.4M | ||
| Q2 25 | $933.8M | $187.4M | ||
| Q1 25 | $912.5M | $192.9M | ||
| Q4 24 | $866.8M | $162.9M | ||
| Q3 24 | $878.6M | $95.0M | ||
| Q2 24 | $873.6M | $70.3M | ||
| Q1 24 | $869.5M | $135.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.06× | ||
| Q3 24 | — | 0.13× | ||
| Q2 24 | — | 0.24× | ||
| Q1 24 | — | 0.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.6M | $-39.6M |
| Free Cash FlowOCF − Capex | $11.2M | $-41.5M |
| FCF MarginFCF / Revenue | 130.9% | -770.4% |
| Capex IntensityCapex / Revenue | 4.9% | 34.8% |
| Cash ConversionOCF / Net Profit | 5.46× | — |
| TTM Free Cash FlowTrailing 4 quarters | $20.3M | $-103.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.6M | $-39.6M | ||
| Q3 25 | $3.7M | $-28.8M | ||
| Q2 25 | $3.8M | $-14.8M | ||
| Q1 25 | $1.9M | $-16.6M | ||
| Q4 24 | $6.8M | $-14.6M | ||
| Q3 24 | $4.1M | $-18.8M | ||
| Q2 24 | $619.0K | $-9.9M | ||
| Q1 24 | $1.2M | $-17.6M |
| Q4 25 | $11.2M | $-41.5M | ||
| Q3 25 | $3.6M | $-29.7M | ||
| Q2 25 | $3.7M | $-15.4M | ||
| Q1 25 | $1.8M | $-16.6M | ||
| Q4 24 | $6.4M | $-14.6M | ||
| Q3 24 | $4.0M | $-18.8M | ||
| Q2 24 | $489.0K | — | ||
| Q1 24 | $1.1M | $-17.7M |
| Q4 25 | 130.9% | -770.4% | ||
| Q3 25 | 43.3% | -904.1% | ||
| Q2 25 | 44.0% | -768.8% | ||
| Q1 25 | 22.7% | -682.8% | ||
| Q4 24 | 83.9% | -566.7% | ||
| Q3 24 | 49.5% | -666.5% | ||
| Q2 24 | 5.9% | — | ||
| Q1 24 | 14.8% | -712.4% |
| Q4 25 | 4.9% | 34.8% | ||
| Q3 25 | 0.8% | 29.2% | ||
| Q2 25 | 1.4% | 26.4% | ||
| Q1 25 | 1.9% | 0.2% | ||
| Q4 24 | 5.6% | 0.1% | ||
| Q3 24 | 1.7% | 0.3% | ||
| Q2 24 | 1.6% | 0.0% | ||
| Q1 24 | 1.8% | 4.4% |
| Q4 25 | 5.46× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 1.75× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 5.05× | — | ||
| Q3 24 | 2.36× | — | ||
| Q2 24 | 0.60× | — | ||
| Q1 24 | 0.91× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AFBI
Segment breakdown not available.
TNXP
| Zembrace Symtouch | $3.1M | 58% |
| Other | $2.3M | 42% |
